Acute megakaryoblastic leukemiaNews & Research

8 curated articles for Acute megakaryoblastic leukemia — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.

ℹ
UniteRare data is compiled from authoritative primary sources (FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, NORD), then processed through automated and AI-assisted extraction pipelines.
Report missing data
  1. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi Apr 16, 2026

    [Acute megakaryoblastic leukemia with CBFA2T3::GLIS2 fusion gene: 3 cases report and literature review].

    This study retrospectively analyzed the clinical manifestations, genetic characteristics, treatment courses, and prognoses of patients with pediatric acute megakaryoblastic leukemia (AMKL) with CBFA2T3::GLIS2 fusion treated at the Institute of Hematology, Chinese Academy of Medical Sciences. Further...

    Why it matters: Recent peer-reviewed research on Acute megakaryoblastic leukemia that may be relevant for patients and caregivers.

  2. EJHaem Apr 10, 2026

    Identification of an Elusive CBFA2T3::GLIS2 Fusion Variant in Acute Megakaryoblastic Leukemia by Whole Genome Sequencing.

    Advancements in genomic profiling have significantly improved the classification and treatment strategies for acute myeloid leukemia (AML). However, widely utilized molecular diagnostic techniques, including targeted gene panels, are often insufficient for detecting complex structural variants, cryp...

    Why it matters: Recent peer-reviewed research on Acute megakaryoblastic leukemia that may be relevant for patients and caregivers.

  3. Trends in molecular medicine Apr 9, 2026

    BH3 mimetic therapies for CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia.

    Pediatric acute megakaryoblastic leukemia (AMKL) associated with the CBFA2T3::GLIS2 (CG2) gene fusion is distinctive by virtue of its aggressiveness and ability to transform normal cells in a single event. The dismal therapeutic response of children to this disease has stimulated comprehensive studi...

    Why it matters: Recent peer-reviewed research on Acute megakaryoblastic leukemia that may be relevant for patients and caregivers.

  4. Blood Apr 8, 2026

    Polycomb repressive complex 2 insufficiency underlies myeloid leukemia in Down syndrome.

    Children with Down syndrome (DS) have an elevated risk of developing myeloid leukemia in DS (ML-DS). In addition to mutations in GATA1, which generate the truncated isoform GATA1-short (GATA1s), ML-DS requires additional somatic gene mutations, most frequently in cohesion and polycomb repressive com...

    Why it matters: Recent peer-reviewed research on Acute megakaryoblastic leukemia that may be relevant for patients and caregivers.

  5. BMC pediatrics Mar 27, 2026

    Acute megakaryoblastic leukemia with myeloid sarcoma among a pediatric patient harbouring RBM15::MRTFA: a case report and literature review.

    Acute megakaryoblastic leukemia with myeloid sarcoma among a pediatric patient harbouring RBM15::MRTFA: a case report and literature review.

    Why it matters: Recent peer-reviewed research on Acute megakaryoblastic leukemia that may be relevant for patients and caregivers.

  6. International journal of hematology Mar 24, 2026

    Acute megakaryoblastic leukemia with RBM15::MKL1 fusion presenting as neonatal acute liver failure: rescued by living-donor liver transplantation.

    Acute liver failure in the neonatal period is commonly caused by infections, metabolic disorders, immune disorders, or neonatal hepatitis-like diseases of unknown etiology; however, malignant diseases are rarely included in the differential diagnosis, and leukemia may be overlooked. We report a case...

    Why it matters: Recent peer-reviewed research on Acute megakaryoblastic leukemia that may be relevant for patients and caregivers.

  7. Cytometry. Part B, Clinical cytometry Mar 10, 2026

    Analysis of immunophenotypic changes in acute megakaryoblastic leukemia after treatment.

    Antigen expression on residual blast cells in acute megakaryoblastic leukemia (AMKL, classified as AML-M7 by FAB criteria) may change after treatment, potentially affecting both immunophenotypic characterization and minimal/measurable residual disease (MRD) monitoring. This study aimed to characteri...

    Why it matters: Recent peer-reviewed research on Acute megakaryoblastic leukemia that may be relevant for patients and caregivers.

  8. Open medicine (Warsaw, Poland) Mar 2, 2026

    Spontaneous remission of congenital acute megakaryoblastic leukemia in a neonate with down syndrome.

    Congenital acute megakaryoblastic leukemia (AMKL) is an extremely rare and aggressive malignancy with poor prognosis. We report a female neonate with Down syndrome (DS) who presented with respiratory distress and hepatomegaly at birth. Laboratory evaluation revealed hyperleukocytosis (253.45 &#...

    Why it matters: Recent peer-reviewed research on Acute megakaryoblastic leukemia that may be relevant for patients and caregivers.

More on Acute megakaryoblastic leukemia

Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.